
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc. is positioned favorably in the biotechnology sector, with its shares currently trading near $4, indicating potential for significant upside contingent upon positive multi-dose data. The company’s Enhanced Delivery Oligonucleotide platform has demonstrated impressive preclinical efficacy, with a 53.7% splicing correction in DM1, surpassing the performance of competitors, thereby suggesting strong therapeutic potential. Additionally, the favorable risk/benefit profile highlighted in discussions underscores the possibility of measurable improvements in muscle performance as multi-dose data progresses, instilling confidence in the company's growth prospects.
Bears say
PepGen Inc. is currently experiencing downward pressure on its stock, with a recent model update reflecting a $1 decrease in its target price to $8 per share. Despite demonstrating potential through its EDO platform, the company's discounted market capitalization appears anomalous compared to its peers, raising concerns about its competitive positioning and execution capabilities. Additionally, the inability to access capital markets could lead to significant delays or even termination of ongoing development campaigns, compounding the negative outlook for the company's financial health.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares